Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients ...

New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and ...

As­traZeneca has great am­bi­tions for its mid-stage oral cho­les­terol drug, be­liev­ing that it could reach peak sales of ...

FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop.

Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing ...

LifeMine restructures with layoffs; PTC's Translarna is pulled in Europe; Opthea ends AMD trials; Apollomics and LaunXP make ...

A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is ...

Isomorphic Labs, one of the leading AI-driven drug discovery companies within Alphabet, has reeled in $600 million in ...

Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 study that could begin at the start of next year.

BiomX's BX211 virus therapy shows promise in Phase 2 trial, reducing foot ulcer size in diabetic bone infection patients ...

SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...

Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...